問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


China Medical University Hospital (在職)

Division of Rheumatology

Division of Dermatology

Division of General Internal Medicine

Taichung Veterans General Hospital (在職)

Division of Rheumatology

Division of General Internal Medicine

China Medical University Hospital-Taipei (在職)

Division of Rheumatology

更新時間：2024-06-04

藍忠亮Lan, Joung-Liang
  • Principal Investigator
  • Clinical Trial Experience (year) 23 years 9 個月

Recruiting Trial

45Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

藍忠亮

List

117Cases

2022-01-12 - 2027-12-31

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting5Sites

2007-05-08 - 2011-05-08

Others

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2005-05-01 - 2007-01-01

Phase II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2022-01-01 - 2026-02-28

Phase I/II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2022-11-01 - 2028-04-30

Phase II/III

xxxxxx

  • Condition/Disease

    xxxxxx

  • Test Drug

    Efgartigimod PH20 SC

Participate Sites
3Sites

Recruiting3Sites

2024-01-15 - 2031-06-30

Phase III

A randomized, double-blind 2-arm NEPTUNUS extension study to assess the long-term safety and efficacy of ianalumab in patients with Sjögren’s syndrome

  • Condition/Disease

    Hughes syndrome

  • Test Drug

    VAY736/ianalumabVAY736/ianalumab

Participate Sites
4Sites

Not yet recruiting3Sites

Recruiting1Sites

2024-07-01 - 2027-11-28

Phase III

An Open-label Extension Trial of the Long-term Safety and Efficacy of BI 1015550 Taken Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF) and Progressive Pulmonary Fibrosis (PPF) (FIBRONEER™-ON)

  • Condition/Disease

    Idiopathic Pulmonary Fibrosis 、Progressive Pulmonary Fibrosis

  • Test Drug

    BI 1015550

Participate Sites
8Sites

Not yet recruiting1Sites

Recruiting7Sites

2007-04-01 - 2011-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2021-01-31 - 2024-04-30

Phase II

A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of the Safety, Tolerability, Pharmacokinetics, and Therapeutic Efficacy of SAR441344 in Adult Patients With Primary Sjögren's Syndrome (pSjS)

  • Condition/Disease

    Primary Sjögren's Syndrome (pSjS)

  • Test Drug

    SAR441344

Participate Sites
4Sites

Not yet recruiting3Sites

Recruiting1Sites

2020-08-27 - 2023-12-18

Phase II

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Guselkumab in Subjects With Active Lupus Nephritis

  • Condition/Disease

    Active Lupus Nephritis

  • Test Drug

    Guselkumab

Participate Sites
4Sites

Recruiting4Sites

1 4 5 6 7 8 12
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB